These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25519701)

  • 1. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
    Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
    Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
    Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
    Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
    Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
    Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
    Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma
    Robinson SP; Boult JKR; Vasudev NS; Reynolds AR
    Cancer Res; 2017 Aug; 77(15):4127-4134. PubMed ID: 28566330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
    Huang D; Ding Y; Zhou M; Rini BI; Petillo D; Qian CN; Kahnoski R; Futreal PA; Furge KA; Teh BT
    Cancer Res; 2010 Feb; 70(3):1063-71. PubMed ID: 20103651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
    Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
    PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
    Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
    Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
    Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
    Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
    Bender C; Ullrich A
    Int J Cancer; 2012 Jul; 131(2):E45-55. PubMed ID: 22020623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
    Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
    Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
    Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
    Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
    Serova M; Tijeras-Raballand A; Dos Santos C; Martinet M; Neuzillet C; Lopez A; Mitchell DC; Bryan BA; Gapihan G; Janin A; Bousquet G; Riveiro ME; Bieche I; Faivre S; Raymond E; de Gramont A
    Oncotarget; 2016 Jun; 7(25):38467-86. PubMed ID: 27509260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.